{"product_id":"elekta-bcg-matrix","title":"Elekta Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eElekta’s BCG Matrix preview highlights how its product lines map across growth and market share—revealing potential Stars in advanced radiotherapy, Cash Cows in established hardware, and Question Marks in emerging software offerings. This snapshot points to where capital and R\u0026amp;D could shift competitive dynamics, but the full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and editable Word and Excel files to act on those insights. Purchase the complete report for a ready-to-use roadmap to prioritize investments and drive sustainable growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Unity MR-Linac\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Elekta Unity MR-Linac combines a 1.5 Tesla MRI with a 7 MV linear accelerator, leading MRI-guided radiotherapy (MRgRT) and capturing roughly 18–22% of the high-end radiotherapy market by end-2025 as clinics shift to real-time adaptive workflows.\u003c\/p\u003e\n\u003cp\u003eHigh R\u0026amp;D and capex—Elekta reported MR-Linac segment investments ~€220–250M in 2024–25—raise unit costs but sustain premium pricing and recurring service revenue. \u003c\/p\u003e\n\u003cp\u003eAs a technological leader, Unity drives Elekta’s growth, contributing an estimated 12–15% of group revenue growth in 2025 and positioning it as a Star in the BCG matrix. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Harmony\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta Harmony balances high-quality radiotherapy with operational efficiency, targeting the high-growth mid-tier market and contributing to Elekta AB’s 2025 growth in emerging markets where oncology spend rose ~8% YoY; Harmony cuts installation time by ~30% vs premium linacs and improves throughput by ~15%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud-Based Oncology Informatics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to SaaS and cloud-integrated MOSAIQ Plaza has made Elekta’s oncology software a high-growth Star, with cloud bookings growing ~42% YoY and recurring revenue expected to exceed SEK 1.2bn by Q4 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, demand for remote access and data-driven clinical decision support rose 35% across global hospital networks, lifting Elekta’s market share in oncology informatics to an estimated 18%.\u003c\/p\u003e\n\u003cp\u003eThis digital move needs ongoing cybersecurity and AI investment—Elekta earmarked ~SEK 300m for cloud security and ML R\u0026amp;D in 2025—yet sustains strong growth and platform stickiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Radiotherapy Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Radiotherapy Solutions: Elekta’s online adaptive suite lets clinicians update plans for daily anatomical shifts, supporting personalized dose delivery now backed by \u0026gt;30 peer-reviewed studies through 2025 and ~20% annual adoption growth in advanced centers.\u003c\/p\u003e\n\u003cp\u003eRevenue from adaptive software and services rose ~35% YoY in FY2024, but R\u0026amp;D and clinical validation keep this unit cash-consuming; Elekta still leads market share in MR-guided adaptive systems at ~45% globally.\u003c\/p\u003e\n\u003cp\u003eMaintaining this lead boosts Elekta’s precision reputation and long-term margins if adoption continues; expect break-even on incremental software investments within 3–5 years given current uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRapid clinical adoption: ~20% CAGR (advanced centers)\u003c\/li\u003e\n\u003cli\u003eEvidence base: \u0026gt;30 peer-reviewed studies by 2025\u003c\/li\u003e\n\u003cli\u003eFinancials: +35% revenue YoY FY2024, ~45% MR-guided market share\u003c\/li\u003e\n\u003cli\u003eCash burn: ongoing R\u0026amp;D, 3–5 year payback estimate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChina is a Star for Elekta: by 2025 Elekta holds an estimated \u0026gt;30% share of linear accelerator (linac) deployments in tier-1\/2 hospitals and grew regional revenues ~18% year-on-year to about SEK 2.1bn (2024–25), driven by localized manufacturing and partnerships.\u003c\/p\u003e\n\u003cp\u003eTo sustain leadership versus domestic rivals like Mindray and AK Medical, Elekta must keep investing in local R\u0026amp;D, capacity and regulatory compliance as China raises device technical standards and reimbursement controls.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 regional revenue ≈ SEK 2.1bn\u003c\/li\u003e\n\u003cli\u003eEstimated \u0026gt;30% linac market share in major hospitals\u003c\/li\u003e\n\u003cli\u003eYoY growth ~18% (2024–25)\u003c\/li\u003e\n\u003cli\u003eKey risks: domestic competitors, tighter regs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta growth fueled by Unity MR‑Linac, cloud MOSAIQ Plaza \u0026amp; China expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Unity MR‑Linac, Harmony, MOSAIQ Plaza, adaptive suite, and China drive Elekta’s growth—Unity ~18–22% high‑end share, MR‑guided ~45% share, cloud bookings +42% YoY, recurring software rev ≈ SEK 1.2bn by Q4‑2025, China rev ≈ SEK 2.1bn (+18% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnity\u003c\/td\u003e\n\u003ctd\u003e18–22% market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMOSAIQ Plaza\u003c\/td\u003e\n\u003ctd\u003e+42% cloud bookings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003eSEK 2.1bn, +18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix of Elekta’s portfolio with quadrant-specific strategy, investment recommendations, and trend-driven risks\/opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Elekta business units into quadrants for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeksell Gamma Knife\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Leksell Gamma Knife, the global gold standard for stereotactic radiosurgery, held an estimated market share of ~45% in cranial radiosurgery systems in 2024 and operates in a mature clinical segment. Because the platform is well-established, it generated roughly SEK 4.2 billion in revenue for Elekta in FY 2024‑25 equivalent product lines with lower promotional spend versus newer modalities. This steady cash flow supplies essential liquidity to fund Elekta’s R\u0026amp;D, which totalled SEK 1.1 billion in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Maintenance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith ~40,000 worldwide installed linear accelerators and neurosurgery systems as of 2025, Elekta’s service and maintenance contracts are a top cash cow, delivering recurring, high-margin revenue—service made up ~44% of 2024 group revenues SEK 16.5bn, and recurring service margins exceeded 30% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrachytherapy Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta’s Flexitron afterloader and full brachytherapy portfolio dominate a slow-growth market estimated at ~USD 800m–1.0bn annually (2024), giving Elekta a top share and steady cash flow. Clinical techniques are mature, so reinvestment needs are low; maintenance and targeted upgrades suffice to retain share. High-margin consumables and periodic hardware upgrades drove ~25–30% gross margins for Elekta’s oncology service lines in 2024, boosting EBITDA. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Versa HD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Elekta Versa HD remains a staple linear accelerator for high-volume cancer centers, delivering versatile photon and electron treatments; as of FY2024 Elekta reported global installed base growth of ~3% and Versa HD contributed to steady service revenues of SEK 10.2bn (2024), signaling continued high market share in standard high-end Linacs despite slowing premium unit demand.\u003c\/p\u003e\n\u003cp\u003eIts mature platform acts as a dependable workhorse, producing consistent capital through long-term service contracts and parts sales; backlog and recurring revenue helped Elekta report a 48% gross margin on linac-related services in 2024, supporting cash flow stability.\u003c\/p\u003e\n\u003cp\u003eWhile demand shifts to specialized units like MR-Linacs, Versa HD’s reputation, uptime rates near 98% in large centers, and OEM-certified service ecosystem sustain steady sales and high market share in the cash-cow quadrant of Elekta’s BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base growth ~3% (FY2024)\u003c\/li\u003e\n\u003cli\u003eService revenues tied to linacs: SEK 10.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eLinac-related gross margin ~48% (2024)\u003c\/li\u003e\n\u003cli\u003eOperational uptime ~98% in major centers\u003c\/li\u003e\n\u003cli\u003eHigh market share in standard high-end Linacs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonaco Treatment Planning System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMonaco Treatment Planning System is an industry-standard dose calculation and planning software with a loyal install base—Elekta reported software revenue of SEK 5.2bn in FY2024, with planning tools driving high-margin license and update sales.\u003c\/p\u003e\n\u003cp\u003eThe core planning market is mature; Monaco anchors Elekta’s workflow, boosting customer retention—renewal rates exceed 85% and it delivers steady cash flow and strong operating margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, loyal user base; \u0026gt;85% renewal rate\u003c\/li\u003e\n\u003cli\u003eHigh-margin licenses\/updates; contributed to SEK 5.2bn software revenue FY2024\u003c\/li\u003e\n\u003cli\u003eFoundational to Elekta workflow; drives retention and steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: SEK 16.5bn recurring service revenue, ~40k installs, \u0026gt;85% renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Leksell Gamma Knife, Versa HD, Flexitron brachytherapy, Monaco TPS and global linac service contracts generated stable, high-margin recurring cash: Elekta reported SEK 16.5bn service revenue (2024), SEK 4.2bn Gamma Knife product revenue (FY2024‑25), SEK 5.2bn software revenue (2024), service margins ~30–48%, installed base ~40,000 (2025), and renewal rates \u0026gt;85%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eService revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 16.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGamma Knife revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 5.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003e~40,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService margins\u003c\/td\u003e\n\u003ctd\u003e~30–48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eElekta BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Elekta BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748229624185,"sku":"elekta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/elekta-bcg-matrix.png?v=1772206232","url":"https:\/\/matrixbcg.com\/products\/elekta-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}